Samsung Bioepis Gets Canadian Trastuzumab Nod
Ontruzant Biosimilar Rival To Herceptin To Be Marketed By Organon In Canada
Executive Summary
Samsung Bioepis has received approval from Health Canada for its Ontruzant trastuzumab biosimilar rival to Herceptin in 150mg single-use and 440mg multi-dose vials. The product will be marketed in Canada by Organon.
You may also be interested in...
Biogen Sells Samsung Bioepis Stake In $2.3bn Buyout
Biogen has struck a deal that will see it sell its equity stake in the Samsung Bioepis biosimilars joint venture to partner Samsung Biologics for up to $2.3bn.
Organon Completes Spin-Out From Merck With Five Biosimilars
With ambitions to continue to invest in its long-standing relationship with Samsung Bioepis, Organon has completed its spin-out from Merck & Co.
Fifth US Biosimilar To Herceptin Launched By Merck
Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.